Dr Dinah Parums Publications
  • Home
  • About
  • Publications
  • Abstracts
  • Books
  • Patents
  • Online Articles
  • Contact

PATENTS

Picture

1) Treatment of Wounds

Application number: 20050148585







Abstract: This invention relates to the use of cyclic guanosine 3?, 5?-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.

Type: Application

Filed: August 26, 2004

Issued: July 7, 2005

Inventors: Michael Davies, Jonathan Huggins, Dinah Parums

2) 12 Amino Acid Sequence

Application number: 20050106638

Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Application

Filed: August 30, 2004

Issued: May 19, 2005

Assignee: Pfizer Inc.

Inventors: Dinah Parums, Stephen Phillips, John Ridden

3) Target

Patent number: 6794192

Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Grant

Filed: June 28, 2001

Issued: September 21, 2004

Assignee: Pfizer Inc.

Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden

4) Target

Application number: 20030040041

Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Application

Filed: June 28, 2001

Issued: February 27, 2003

Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden

5) Treatment of wounds

Application number: 20020065286

Abstract: This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.

Type: Application

Filed: August 10, 2001

Issued: May 30, 2002

Inventors: Michael John Davies, Jonathan Paul Huggins, Dinah Parums


Proudly powered by Weebly